Amgen halted a clinical trial of its Vectibix drug as part of a chemotherapy regimen with Avastin for treating metastatic colorectal cancer, saying the combo actually hindered survival. The company said an interim analysis of the trial results showed a significant negative response when Vectibix was added to the existing treatment of Genentech's Avastin and chemotherapy.

Related Summaries